Royalty Pharma (FRA:RPD) Other Current Receivables: €24 Mil (As of Mar. 2026)


FRA:RPD Royalty Pharma PLC FRA:RPD
67 GF Score
Price €49.38
GF Value €32.48
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Other Current Receivables?

Royalty Pharma FRA:RPD -2.42% 67 Other Current Receivables is €24 Mil as of Mar. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 67/100 and a GF Value™ of €32.48 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Royalty Pharma's Other Current Receivables for the quarter that ended in Mar. 2026 was €24 Mil.

Royalty Pharma's quarterly Other Current Receivables increased from Sep. 2025 (€24.62 Mil) to Dec. 2025 (€25.04 Mil) but then stayed the same from Dec. 2025 (€25.04 Mil) to Mar. 2026 (€23.80 Mil).

Royalty Pharma's annual Other Current Receivables increased from Dec. 2023 (€20.55 Mil) to Dec. 2024 (€25.74 Mil) but then declined from Dec. 2024 (€25.74 Mil) to Dec. 2025 (€25.04 Mil).

Royalty Pharma Other Current Receivables Related Terms

Royalty Pharma Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Other Current Receivables Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only 60.45 34.55 20.55 25.74 25.04

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.00 24.05 24.62 25.04 23.80
FRA:RPD
67GF Score
Royalty Pharma PLC FRA:RPD
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €24 Mil mean?
Royalty Pharma (FRA:RPD) has a Other Current Receivables of €24 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Other Current Receivables too high?
Royalty Pharma's current Other Current Receivables is €24 Mil. Overall, Royalty Pharma has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Other Current Receivables compare to ROIV and MRNA?
Royalty Pharma's Other Current Receivables of €24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Other Current Receivables is €24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.48, compared to a current price of €49.38 — trading 52% above its estimated fair value. The current Other Current Receivables is €24 Mil. Royalty Pharma's overall GF Score™ is 67/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Other Current Receivables is €24 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €49.38 is trading 52% above its estimated GF Value™ of €32.48. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Other Current Receivables: €24 Mil
  • GF Value™: €32.48 vs. price of €49.38 (52% above fair value)
  • GF Score™: 67/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
67GF Score

Get the complete analysis for FRA:RPD

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€49.38
Price
€32.48
GF Value